Alterity Therapeutics Ltd ADR ATHE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.12
- Day Range
- $2.91–3.09
- 52-Week Range
- $2.66–5.89
- Bid/Ask
- $2.95 / $2.99
- Shares Outstanding
- 18.21M
- Market Cap
- $53.90M
- Volume/Avg
- 10,193 / 16,715
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 11
Valuation
|
Metric
|
ATHE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.22 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATHE
|
|---|---|
Quick Ratio | 14.26 |
Current Ratio | 14.52 |
Interest Coverage | — |
Quick Ratio
ATHE
Profitability
|
Metric
|
ATHE
|
|---|---|
Return on Assets (Normalized) | −40.79% |
Return on Equity (Normalized) | −49.76% |
Return on Invested Capital (Normalized) | −46.03% |
Return on Assets
ATHE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%JTwF>Q | LOCK|tfJj% | $129B | |||
| Moderna Inc
MRNA
| LOCK|#JbdBt | LOCK|R& | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|mTW!R% | LOCK|jnq>$ | $77B | |||
| argenx SE ADR
ARGX
| LOCK|^cfKD?% | LOCK|&f | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?%?!Qf | LOCK|!@ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|dk%Z<p | LOCK|>@@l | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Bp>H?%$^ | LOCK|Dx@Z | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|mwYRQbL | LOCK|QB | $24B | |||
| Incyte Corp
INCY
| LOCK|g@#?$G | LOCK|>z | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|xMb#^x | LOCK|Gj> | $14B |
United States